WEBSITE BSE:506820 NSE: ASTRAZEN.PH. Inc. Year: 1979 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:57
AstraZeneca Pharma India Ltd is a biopharmaceutical corporation. The Company makes a speciality of the invention, development and commercialization of prescription medicines, broadly speaking for the remedy of illnesses in 3 therapy regions, along with oncology, cardiovascular, renal and metabolism, and breathing. It additionally offers clinical trial services. Its cardiovascular disease and diabetic medicine brands consist of Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL and Xigduo XR. Its respiratory medicinal...Read More
AstraZeneca Pharma India Ltd is a biopharmaceutical corporation. The Company makes a speciality of the invention, development and commercialization of prescription medicines, broadly speaking for the remedy of illnesses in 3 therapy regions, along with oncology, cardiovascular, renal and metabolism, and breathing. It additionally offers clinical trial services. Its cardiovascular disease and diabetic medicine brands consist of Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL and Xigduo XR. Its respiratory medicinal drug manufacturers encompass Symbicort and FASENRA. Its oncology medication brands consist of LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex and Arimidex. It offers offerings, along with self-management, diabetes food regimen and nutrients plans, and free telephonic counseling to patients. It operates in over one hundred international locations. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹21266 Cr.
Stock P/E 183.7
P/B 25.6
Current Price ₹8506.5
Book Value ₹ 332.6
Face Value 2
52W High ₹10653.1
Dividend Yield 0.38%
52W Low ₹ 7630
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 | 612 |
| Other Income | 8 | 10 | 9 | 8 | 8 | 8 | 16 | 11 | 6 | 5 |
| Total Income | 319 | 315 | 392 | 396 | 416 | 448 | 497 | 538 | 565 | 617 |
| Total Expenditure | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 |
| Operating Profit | 61 | 25 | 58 | 46 | 61 | 85 | 103 | 92 | 81 | 50 |
| Interest | 1 | 1 | -0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 | 4 |
| Exceptional Income / Expenses | 16 | 0 | 0 | -58 | 0 | -34 | -6 | -0 | -5 | 1 |
| Profit Before Tax | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 | 73 | 47 |
| Provision for Tax | 21 | 5 | 15 | -3 | 13 | 11 | 20 | 19 | 19 | 14 |
| Profit After Tax | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 | 33 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 | 33 |
| Adjusted Earnings Per Share | 20.9 | 6.3 | 15.8 | -4.7 | 15.4 | 12.3 | 23.3 | 22.3 | 21.7 | 13 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1003 | 1296 | 1716 | 2177 |
| Other Income | 8 | 7 | 14 | 12 | 16 | 13 | 13 | 15 | 26 | 35 | 41 | 38 |
| Total Income | 525 | 571 | 558 | 583 | 745 | 845 | 826 | 820 | 1029 | 1330 | 1757 | 2217 |
| Total Expenditure | 531 | 547 | 507 | 525 | 657 | 711 | 678 | 719 | 838 | 1111 | 1462 | 1890 |
| Operating Profit | -6 | 23 | 51 | 59 | 88 | 134 | 148 | 101 | 191 | 219 | 295 | 326 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 4 |
| Depreciation | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 42 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -40 | 16 | -97 | -10 |
| Profit Before Tax | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 273 |
| Provision for Tax | 0 | 1 | 15 | 18 | 18 | 42 | 34 | 21 | 35 | 58 | 41 | 72 |
| Profit After Tax | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 201 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 201 |
| Adjusted Earnings Per Share | -8.3 | 2.1 | 8 | 10.4 | 21.8 | 28.9 | 37.3 | 24.6 | 39.7 | 64.6 | 46.3 | 80.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 32% | 29% | 16% | 13% |
| Operating Profit CAGR | 35% | 43% | 17% | 0% |
| PAT CAGR | -28% | 23% | 10% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -3% | 38% | 19% | 22% |
| ROE Average | 16% | 20% | 19% | 14% |
| ROCE Average | 21% | 27% | 26% | 20% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 151 | 156 | 223 | 247 | 301 | 364 | 456 | 511 | 589 | 712 | 770 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1 | 39 | 89 | 110 | 23 | 44 | 45 | 74 | 69 | 98 | 159 |
| Total Current Liabilities | 260 | 234 | 202 | 219 | 268 | 367 | 373 | 392 | 484 | 467 | 908 |
| Total Liabilities | 412 | 429 | 514 | 575 | 591 | 776 | 874 | 977 | 1142 | 1277 | 1838 |
| Fixed Assets | 101 | 97 | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 | 64 |
| Other Non-Current Assets | 47 | 65 | 164 | 167 | 103 | 122 | 105 | 138 | 137 | 167 | 226 |
| Total Current Assets | 263 | 267 | 263 | 333 | 413 | 582 | 689 | 765 | 936 | 1043 | 1548 |
| Total Assets | 412 | 429 | 514 | 575 | 591 | 776 | 874 | 977 | 1142 | 1277 | 1838 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 88 | 23 | 76 | 115 | 114 | 173 | 84 | 352 | 448 | 500 | 506 |
| Cash Flow from Operating Activities | -46 | 57 | 38 | 9 | 55 | 87 | 105 | 101 | 58 | 28 | 65 |
| Cash Flow from Investing Activities | -19 | -4 | 0 | -9 | 4 | -171 | 173 | 5 | 18 | 22 | 31 |
| Cash Flow from Financing Activities | 0 | -1 | 0 | 0 | 0 | -6 | -9 | -9 | -24 | -44 | -66 |
| Net Cash Inflow / Outflow | -64 | 53 | 38 | -1 | 59 | -90 | 269 | 96 | 52 | 5 | 31 |
| Closing Cash & Cash Equivalent | 23 | 76 | 115 | 114 | 173 | 84 | 352 | 448 | 500 | 506 | 536 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -8.34 | 2.1 | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.6 | 46.3 |
| CEPS(Rs) | -2.22 | 9.07 | 14.35 | 16.26 | 27.75 | 36.32 | 45.37 | 31.42 | 46.22 | 70.58 | 62.29 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 10 | 16 | 24 | 32 |
| Book NAV/Share(Rs) | 60.3 | 62.41 | 88.49 | 97.94 | 119.48 | 145.14 | 181.83 | 203.78 | 234.45 | 283.45 | 305.28 |
| Core EBITDA Margin(%) | -2.59 | 2.88 | 6.73 | 8.09 | 9.74 | 14.45 | 16.58 | 10.65 | 16.39 | 14.17 | 14.74 |
| EBIT Margin(%) | -3.97 | 1.01 | 6.47 | 7.66 | 9.93 | 13.78 | 15.69 | 10.38 | 13.37 | 16.95 | 9.16 |
| Pre Tax Margin(%) | -3.97 | 1.01 | 6.47 | 7.66 | 9.93 | 13.64 | 15.56 | 10.26 | 13.31 | 16.86 | 9.08 |
| PAT Margin (%) | -3.97 | 0.92 | 3.65 | 4.53 | 7.44 | 8.65 | 11.42 | 7.61 | 9.85 | 12.4 | 6.72 |
| Cash Profit Margin (%) | -1.06 | 3.98 | 6.54 | 7.11 | 9.48 | 10.87 | 13.88 | 9.7 | 11.47 | 13.55 | 9.04 |
| ROA(%) | -5.04 | 1.25 | 4.25 | 4.76 | 9.34 | 10.57 | 11.31 | 6.65 | 9.37 | 13.35 | 7.43 |
| ROE(%) | -12.93 | 3.43 | 10.63 | 11.12 | 20.03 | 21.83 | 22.83 | 12.78 | 18.13 | 24.95 | 15.73 |
| ROCE(%) | -12.93 | 3.76 | 18.74 | 18.65 | 26.53 | 34.61 | 31.24 | 17.36 | 24.49 | 33.94 | 21.29 |
| Receivable days | 33.27 | 40.32 | 41.96 | 31.15 | 33.52 | 35.61 | 37.62 | 38.57 | 35.03 | 36.53 | 35.81 |
| Inventory Days | 63.23 | 52.15 | 44.72 | 54.51 | 57.68 | 61.89 | 72.59 | 67.64 | 59.85 | 58.6 | 82.25 |
| Payable days | 207.79 | 192.9 | 194.34 | 220.03 | 237.77 | 229.92 | 246.52 | 220.48 | 214.92 | 131.27 | 124.39 |
| PER(x) | 0 | 549.84 | 117.29 | 89.4 | 91.75 | 82.8 | 80.66 | 103.71 | 81.76 | 82.35 | 185.9 |
| Price/Book(x) | 15.22 | 18.53 | 10.63 | 9.46 | 16.72 | 16.48 | 16.55 | 12.54 | 13.85 | 18.77 | 28.19 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0.04 | 0.07 | 0.39 | 0.49 | 0.45 | 0.37 |
| EV/Net Sales(x) | 4.39 | 4.99 | 4.11 | 3.84 | 6.62 | 6.88 | 8.82 | 7.37 | 7.6 | 9.88 | 12.22 |
| EV/Core EBITDA(x) | -408.16 | 121.38 | 43.56 | 37.42 | 55.06 | 42.83 | 48.37 | 58.85 | 39.84 | 58.36 | 71.21 |
| Net Sales Growth(%) | 9.09 | 9.02 | -3.55 | 5.02 | 27.55 | 14.21 | -2.19 | -0.98 | 24.5 | 29.17 | 32.48 |
| EBIT Growth(%) | 0 | 127.66 | 515.93 | 23.38 | 65.91 | 58.4 | 11.35 | -34.48 | 60.41 | 63.84 | -28.5 |
| PAT Growth(%) | -3994.91 | 125.24 | 281.25 | 29.23 | 110.15 | 32.62 | 29.21 | -33.98 | 61.19 | 62.66 | -28.34 |
| EPS Growth(%) | -3994.25 | 125.24 | 281.25 | 29.23 | 110.15 | 32.62 | 29.21 | -33.98 | 61.19 | 62.66 | -28.34 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 1.01 | 1.14 | 1.3 | 1.52 | 1.54 | 1.59 | 1.84 | 1.95 | 1.93 | 2.23 | 1.7 |
| Quick Ratio(x) | 0.68 | 0.81 | 1.02 | 1 | 1.1 | 1.14 | 1.42 | 1.59 | 1.54 | 1.74 | 1.1 |
| Interest Cover(x) | 0 | 0 | 0 | 0 | 0 | 100.97 | 117.6 | 88.41 | 213.86 | 183.95 | 108.1 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 |
| FII | 2.69 | 2.65 | 2.74 | 2.79 | 2.9 | 2.93 | 2.89 | 3.03 | 2.74 | 2.71 |
| DII | 2.42 | 2.77 | 3.77 | 5 | 5.09 | 5.21 | 4.64 | 4.55 | 5.25 | 5.55 |
| Public | 19.9 | 19.58 | 18.5 | 17.21 | 17.02 | 16.87 | 17.48 | 17.42 | 17.02 | 16.75 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.88 | 1.88 | 1.88 | 1.88 | 1.88 | 1.88 | 1.88 | 1.88 | 1.88 | 1.88 |
| FII | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.07 | 0.07 |
| DII | 0.06 | 0.07 | 0.09 | 0.12 | 0.13 | 0.13 | 0.12 | 0.11 | 0.13 | 0.14 |
| Public | 0.5 | 0.49 | 0.46 | 0.43 | 0.43 | 0.42 | 0.44 | 0.44 | 0.43 | 0.42 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
